Skip to main content
Clinical Trials/JPRN-UMIN000028116
JPRN-UMIN000028116
Recruiting
Phase 2

Phase II study of chemoradiotherapy combined with gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer - NUPAT 05

agoya University Pancreatic Tumor Bord0 sites25 target enrollmentAugust 1, 2017

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
nresectable locally advanced pancreatic cancer
Sponsor
agoya University Pancreatic Tumor Bord
Enrollment
25
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 1, 2017
End Date
December 4, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
agoya University Pancreatic Tumor Bord

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Distant metastasis 2\) Allergy to gemcitabine or nab\-paclitaxel 3\) Invasion to digestive tract 4\) Severe allergy to drags 5\) Infection 6\) Severe cardiovascular disease 7\) Severe basal disease 8\) Double cancer 9\) Peripheral sensory neuropathy or myelopathy 10\) ascites or pleural effusion 11\) Active digestive tract bleeding 12\) Severe diarrhea 13\) Fibroid lung 14\) History of radiotherapy for abdomen 15\) Uncontrolled cancer pain 16\) Lung would be included within radiation field 17\) Uncontrolled severe mental disease 18\) Pregnant 19\) Not obtained consent to this trail 20\) Not appropriate for the study at the physician's assessment.

Outcomes

Primary Outcomes

Not specified

Similar Trials